Iatrogenic Ozurdex® injection into the crystalline lens and surgical management

• Published in: Acta ophthalmologica (Oxford, England) Vol. 94; no. S256
• Main Authors: Sanchez marin, J.I., Ascaso, F., Pérez Navarro, I., Almenara, C., Martínez V, M., Estebán Floría, O., Idoate, A., Berniolles, J., Bartolomé, I.
• Format: Journal Article
• Language: English
• Published: Malden Wiley Subscription Services, Inc 01.10.2016
• Subjects: Cataracts; Dexamethasone; Diabetes mellitus; Diabetic retinopathy; Edema; Iatrogenesis; Implantation; Injection; Management methods; Occlusion; Ophthalmology; Retina; Retinopathy; Surgery; Tearing; Transplants & implants
• ISSN: 1755-375X; 1755-3768
• DOI: 10.1111/j.1755-3768.2016.0585

Purpose Ozurdex® implant is a 700 micrograms implant of Dexamethasone approved for the treatment of macular edema secondary to diabetic retinopathy or retinal vein occlusion. The purpose is to describe the uncommon Ozurdex® injection into the crystalline lens and its management. Methods We present the case of a woman diagnosed with cystoid macular edema who underwent intravitreal Ozurdex® injection. During the procedure the implant was accidentally injected into the lens body. We also discuss about the surgical management of this complication. Results The patient was scheduled for phacoemulsification surgery of the lens with implantation of a 3‐piece lens into the sulcus because a tear in the posterior capsule was identified during the surgery. Conclusions Few problems involving the anterior segment in Ozurdex® implants have been described. However, the injection of the dispositive into the crystalline lens is a rare complication we must take into account. Cataract surgery should be performed as soon as possible and we must keep in mind the posible damage of the structures such as posterior capsule or lens zonules. We recommend the management of these cases with a 3‐pieces IOL into the sulcus.